DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The "Hyperuricemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Hyperuricemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Hyperuricemia . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Hyperuricemia marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

This report provides a comprehensive understanding of the emerging Phase III therapies for Hyperuricemia which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Hyperuricemia: Overview3. Comparative Analysis of Marketed and Emerging Products4. Marketed Therapies

5. Emerging Therapies (Phase III)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gbth8z/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005894/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/06/2018 03:37 PM/DISC: 09/06/2018 03:37 PM

http://www.businesswire.com/news/home/20180906005894/en